MX2017011910A - Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2. - Google Patents

Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2.

Info

Publication number
MX2017011910A
MX2017011910A MX2017011910A MX2017011910A MX2017011910A MX 2017011910 A MX2017011910 A MX 2017011910A MX 2017011910 A MX2017011910 A MX 2017011910A MX 2017011910 A MX2017011910 A MX 2017011910A MX 2017011910 A MX2017011910 A MX 2017011910A
Authority
MX
Mexico
Prior art keywords
type
diabetes
assessment
tools
prevention
Prior art date
Application number
MX2017011910A
Other languages
English (en)
Inventor
Simon Buela Laureano
G Zulueta Mirella
Original Assignee
Patia Biopharma S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patia Biopharma S A De C V filed Critical Patia Biopharma S A De C V
Publication of MX2017011910A publication Critical patent/MX2017011910A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención provee un método para evaluar la susceptibilidad a la diabetes tipo 2 y/o predecir la respuesta al tratamiento en un sujeto humano, el que comprende determinar la identidad de al menos un alelo en cada una de tres o más posiciones de polimorfismo de nucleótido simple (SNP) seleccionadas del grupo que consiste en: SLC16A11 - rs75493593, HNF1A - rs483353044; TCF7L2 - rs7903146, CDKN2A/B - rs10811661, CDKAL1 - rs7756992, SLC30A8 - rs3802177, IGF2BP2 - rs4402960, FTO - rs9936385, PPARG - rs1801282, HHEX/IDE - rs1111875, ADCY5 - rs11717195, JAZF1 - rs849135, WSF1 - rs4458523, INS-IGF2 - rs149483638, KCNQ1 - rs2237897 y KCNJ11 - rs5219, y/o un SNP con desequilibrio de enlace con cualquiera de dichos SNP a r2>0.8. También se proveen una herramienta de genotipado y un sistema de evaluación de riesgo de diabetes tipo 2 a utilizar en el método de la invención.
MX2017011910A 2015-03-18 2016-03-18 Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2. MX2017011910A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1504607.1A GB201504607D0 (en) 2015-03-18 2015-03-18 Methods,tools and systems for the assessment,preventation,management and treatment selection for type 2 diabetes
PCT/EP2016/055949 WO2016146811A1 (en) 2015-03-18 2016-03-18 Methods, tools and systems for the assessment, prevention, management and treatment selection for type 2 diabetes

Publications (1)

Publication Number Publication Date
MX2017011910A true MX2017011910A (es) 2018-08-28

Family

ID=53052023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011910A MX2017011910A (es) 2015-03-18 2016-03-18 Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2.

Country Status (8)

Country Link
US (2) US20180094318A1 (es)
EP (1) EP3271476B1 (es)
JP (1) JP6751418B2 (es)
DK (1) DK3271476T3 (es)
ES (1) ES2794950T3 (es)
GB (1) GB201504607D0 (es)
MX (1) MX2017011910A (es)
WO (1) WO2016146811A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210254164A1 (en) * 2018-06-15 2021-08-19 Opti-Thera Inc. Polygenic risk scores for predicting disease complications and/or response to therapy
JP6688418B1 (ja) * 2019-04-16 2020-04-28 ジェネシスヘルスケア株式会社 ２型糖尿病のリスクを判定する方法
WO2021170504A1 (en) * 2020-02-25 2021-09-02 Ling Charlotte Dna methylation level of specific cpg sites for prediction of glycemic response and tolerance to metformin treatment in type 2 diabetic patients
CN113393896A (zh) * 2021-06-11 2021-09-14 成都果壳医学科技有限公司 一种基于深度神经网络的i型糖尿病风险评估系统
WO2024080651A1 (ko) * 2022-10-12 2024-04-18 서울대학교병원 Thada 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
KR20240051814A (ko) * 2022-10-12 2024-04-22 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210272B1 (en) 1997-12-22 2001-04-03 Health Hero Network, Inc. Multi-player interactive electronic game for health education
JP5033392B2 (ja) 2006-03-10 2012-09-26 国立大学法人三重大学 ２型糖尿病の遺伝的リスク検出法
US20090299645A1 (en) 2008-03-19 2009-12-03 Brandon Colby Genetic analysis
AU2010269841A1 (en) * 2009-07-10 2012-02-23 Decode Genetics Ehf Genetic markers associated with risk of diabetes mellitus

Also Published As

Publication number Publication date
DK3271476T3 (da) 2020-06-08
US11578368B2 (en) 2023-02-14
ES2794950T3 (es) 2020-11-19
GB201504607D0 (en) 2015-05-06
EP3271476B1 (en) 2020-03-04
WO2016146811A1 (en) 2016-09-22
JP6751418B2 (ja) 2020-09-09
JP2018515128A (ja) 2018-06-14
US20180094318A1 (en) 2018-04-05
EP3271476A1 (en) 2018-01-24
US20200318192A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
MX2017011910A (es) Métodos, herramientas y sistemas para la evaluación, prevención, manejo y selección de tratamiento para diabetes tipo 2.
CY1125362T1 (el) Διαχωρισμος γονιδιωματικων κλασματων με χρηση των μετρησεων πολυμορφισμων
Schmickl et al. Arabidopsis hybrid speciation processes
WO2014116729A3 (en) Haplotying of hla loci with ultra-deep shotgun sequencing
WO2015164432A8 (en) Detecting mutations and ploidy in chromosomal segments
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
WO2015200701A3 (en) Software haplotying of hla loci
GB2477868A (en) Methods and systems for incorporating multiple environmental and genetic risk factors
GB2558458A (en) Predicting disease burden from genome variants
EP3626832A3 (en) Method of identifying and treating a person having a predisposition to or afflicted with a cardiometabolic disease
WO2008089465A3 (en) Gene polymorphisms as sex-specific predictors in cancer therapy
WO2015006643A3 (en) Systems, methods, and environment for automated review of genomic data to identify downregulated and/or upregulated gene expression indicative of a disease or condition
PH12019502238A1 (en) Systems and methods for use in identifying multiple genome edits and predicting the aggregate effects of the identified genome edits
WO2010103292A3 (en) A genotyping tool for improving the prognostic and clinical management of ms patients
MX350967B (es) Marcadores geneticos para myb28.
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
WO2016176451A3 (en) System and method for processing genotype information relating to nsaid risk
WO2005112568A3 (en) Haplotype markers and methods of using the same to determine response to treatment
MX2017011511A (es) Manejo y control de la infeccion.
WO2016156576A9 (en) Method of treatment using genetic predictors of a response to treatment with crhr1 antagonists
MX2017011512A (es) Metodos de visualizacion de la sensibilidad antimicrobiana de cepas aisladas biologicas.
WO2011146788A3 (en) Methods of assessing a risk of developing necrotizing meningoencephalitis
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
EP3315613A3 (en) Methods and kits for diagnosing or assessing the risk of cervical cancer
AR104348A1 (es) Polimorfismos de un solo nucleótido seleccionados que son predictivos de respuestas al acetato de glatirámero

Legal Events

Date Code Title Description
FG Grant or registration